Core Viewpoint - The company faced significant revenue decline in 2024 due to market environment changes and centralized procurement policies, impacting its financial performance and product sales [1][2]. Financial Performance - In 2024, the company reported total revenue of 437 million yuan, a decrease of 19.53% year-on-year, with a net profit attributable to shareholders of 35 million yuan, down 61.37% [1]. - For Q4 2024, revenue was 116 million yuan, a decline of 18.19%, and net profit attributable to shareholders was 10 million yuan, down 78.19% [1]. - In Q1 2025, revenue was 75 million yuan, a decrease of 19.53%, but the company achieved a net profit of 470,000 yuan, marking a return to profitability [1]. Market Impact - The implementation of centralized procurement led to a significant drop in revenue from HPV products, which saw a year-on-year decline of 31.38% [2]. - Revenue from third-party testing clients decreased by 51.17% due to price sensitivity, while direct sales to third-party and screening clients fell by 31.76% [2]. - Revenue from hospital clients, which are less affected by centralized procurement, declined by 13.70%, indicating a more stable revenue stream compared to other client segments [2]. R&D and Strategic Initiatives - The company increased its R&D expenditure to 15.05% of revenue, focusing on over 70 projects across various technology platforms [3]. - Clinical research for cervical cancer screening and expansion of methylation detection sample types were completed in 2024 [3]. - The company entered the fungal detection field through acquisitions and invested in dry eye disease and AI sectors, enhancing its innovation pipeline [3]. Future Outlook - The company anticipates continued pressure in Q1 2025 due to industry policies and reduced HPV usage among price-sensitive clients [3]. - Projected net profits for 2025-2027 are estimated at 40 million, 50 million, and 60 million yuan, reflecting year-on-year growth rates of 5.7%, 27.2%, and 32.9% respectively [3]. - The company's reasonable market value is estimated at 2.6 billion yuan, with a target price of 16 yuan per share, maintaining a "recommended" rating [3].

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 16 yuan [2][8]. Core Views - The company's performance is under pressure, with a significant decline in revenue and net profit for 2024. The total revenue for 2024 is reported at 437 million yuan, down 19.53% year-on-year, and the net profit attributable to the parent company is 34 million yuan, down 61.4% [2][4]. - The company is focusing on self-research and acquisitions to enrich its product pipeline, with a research and development expense ratio of 15.05% in 2024. The company has completed clinical research for cervical cancer screening and expanded its methylation detection sample types [2][8]. - The first quarter of 2025 continues to show pressure, with revenue of 75 million yuan, down 19.53% year-on-year, but the company managed to turn a profit with a net profit of 470,000 yuan [2][4]. Financial Summary - For 2024, the total revenue is 437 million yuan, with a year-on-year growth rate of -19.5%. The net profit attributable to the parent company is 34 million yuan, with a year-on-year growth rate of -61.4% [4]. - The projected financials for 2025 to 2027 show a gradual recovery, with net profits expected to grow to 36 million yuan in 2025, 46 million yuan in 2026, and 62 million yuan in 2027, reflecting growth rates of 5.7%, 27.2%, and 32.9% respectively [4][8]. - The company's earnings per share (EPS) is projected to be 0.21 yuan in 2024, increasing to 0.22 yuan in 2025, 0.28 yuan in 2026, and 0.38 yuan in 2027 [4][8].

Group 1: Company Overview - The company is Shanghai TuoJing Life Science Technology Co., Ltd., which held an annual performance briefing on May 15, 2025 [2][4]. - Key attendees included the Chairman and General Manager Mr. Yao Jian'er, Vice General Manager and Secretary of the Board Mr. Wang Xiaoqing, Financial Officer Mr. Li Songtao, and Independent Director Mr. Zhao Jiaxiang [2][4]. Group 2: Financial Performance and Share Buyback - In 2024, the company executed a share buyback plan with a total expenditure of RMB 25,979,178.00 (excluding transaction fees) [5]. - A new share buyback plan was approved on April 8, 2025, with a budget of RMB 20 million to 40 million, aimed at supporting stockholder rights and future employee stock ownership plans [5]. Group 3: Cost Reduction and Efficiency Measures - The company has implemented several cost reduction and efficiency measures in response to industry-wide procurement initiatives, including optimizing production processes and relocating low-margin products to lower-cost facilities [5]. - These measures aim to stabilize the overall gross margin and reduce depreciation costs associated with equipment installation [5]. Group 4: Research and Development Achievements - The company has prioritized R&D, participating in national key projects and being recognized as a high-tech enterprise and a "little giant" in specialized fields [6]. - As of the end of 2024, the company has filed 57 invention patents, with 27 granted, and has launched several pioneering products in clinical diagnostics [6]. - Future R&D investments will focus on areas such as oncology, autoimmune diseases, thrombosis, infectious diseases, and cytokines [6].

证券代码：300642 证券简称：透景生命 公告编号：2025-037 上海透景生命科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 二、对公司的影响及风险提示 上述医疗器械注册证的取得，丰富了公司及江西透景在流式荧光产品线的布 局，巩固了公司在高通量流式荧光技术平台上的优势地位，同时更加满足终端用 户对皮肌炎/多发性肌炎、免疫介导的坏死性肌病、肌炎/重叠综合征、干燥综合 征、系统硬化症等自身免疫疾病相关检测项目的临床诊断需求，将进一步增强公 司及子公司体外诊断领域的综合竞争力，有利于进一步提高市场拓展能力，对公 司未来的生产经营将产生正面影响。 上述产品实际销售使用情况取决于未来市场的推广效果，目前尚无法预测上 述产品对公司未来业绩的影响，敬请投资者注意防范投资风险。 三、备查文件 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"）的全资子公司江西透 景生命科技有限公司（以下简称"子公司"或"江西透景"）于近日取得江西省 药品监督管理局颁发的 1 项医疗器械注册证，具体情况如下： | 产品名称 | 注册证 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-036 上海透景生命科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 2、自分配方案披露至实施期间，公司股本总额未发生变化。本次实施的分 配方案与股东大会审议通过的分配方案及其调整原则保持一致。 3、本次实施分配方案距离股东大会审议通过的时间未超过两个月。 二、本次实施的利润分配方案 1、上海透景生命科技股份有限公司（以下简称"公司"或"本公司"）2024 年度利润分配方案为：以 2024 年年度权益分派股权登记日的公司总股本扣减回 购专户股份后的公司股份总数为基数，向全体股东每 10 股派发现金股利 1.50 元（含税）；本次利润分配不送红股、不进行资本公积金转增股本。本次权益分 派实际现金分红总额=实际参与现金分红的股本×分配比例=（总股本-已回购股 份）×每 10 股现金分红/10 股=（163,021,941 股-1,946,150 股）×1.50 元/10 股=24,161,368.65 元（含税）。 2、截止本公告披露日，公 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-035 上海透景生命科技股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议届次：2024 年度股东大会。 2、会议召集人：上海透景生命科技股份有限公司（以下简称"公司"或"透 景生命"）董事会。经公司第四届董事会第九次会议审议通过，决定召开公司 2024 年度股东大会。 3、会议召开的合法、合规性：本次会议召集程序符合有关法律、行政法规、 部门规章、规范性文件和公司章程的有关规定，合法有效。 4、会议召开的日期、时间： （1）现场会议时间：2025 年 5 月 9 日（星期五）14:00 （2）网络投票时间： 通过深圳证券交易所证券交易系统进行网络投票的具体时间为：2025 年 5 月 9 日的交易时间，即 9:15—9:25，9:30—11:30 和 13:00—15:00。 通过深圳证券交易所互联网投票系统（ht ...

关于上海透景生命科技股份有限公司 2024 年度股东大会 法 律 意 见 书 致：上海透景生命科技股份有限公司 上海市光大律师事务所接受上海透景生命科技股份有限公司（以 下简称"公司"）的委托，指派潘轶、程安卿律师（以下简称"本律 师"）就公司于 2025 年 5 月 9 日召开的 2024 年度股东大会（以下简 称"本次股东大会"）相关事宜，根据《中华人民共和国公司法》、《深 圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》（以下简称"规范性 文件"）和《上海透景生命科技股份有限公司章程》（以下简称"公司 章程"）的规定，出具法律意见书。 为出具法律意见书，本律师审查了公司提供的有关召集、召开本 次股东大会的文件材料,并出席本次股东大会进行现场见证。 在法律意见书中，本律师根据法律意见书出具日以前发生的事实 及对该事实的了解，对公司本次股东大会所涉及的法律问题发表法律 意见,并依法对法律意见书承担责任。 本律师同意，公司可以将法律意见书作为本次股东大会的法定文 件,随同本次股东大会决议一并公告。 本律师按照律师行业公认的业务标准、道德规范和勤勉尽 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-034 截至 2025 年 4 月 30 日，公司通过股票回购专用账户以集中竞价交易方式累 计回购股份 0 股，占公司当前总股本的 0%，支付的总金额为人民币 0 元（不含 交易费用）。 二、其他说明 公司后续将根据市场情况在本次回购股份方案规定的回购期限内择机做出 回购决策并予以实施，并将在回购期间根据相关法律、法规和规范性文件的规定 及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 上海透景生命科技股份有限公司 董 事 会 上海透景生命科技股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 4 月 8 日 召开第四届董事会第八次会议，审议通过了《关于以集中竞价交易方式回购公司 股份的议案》。本次回购的股份用于股权激励或员工持股计划，用于回购股份的 资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万元（含），实 施期限为自公司董事会审议通过本次回购股份方案 ...

Financial Performance - In Q1 2025, the company achieved revenue of 74.89 million yuan, a year-on-year decrease of 19.53%, primarily due to industry policy impacts and reduced HPV usage from price-sensitive ICL customers [4] - The company maintained a gross margin stability through cost control measures, resulting in a notable recovery in net profit for Q1 2025 compared to the previous year [5] Asset Management - The company recognized asset impairment provisions totaling 5.59 million yuan in Q1 2025, which reduced net profit by 4.75 million yuan [6] - The largest impact on impairment provisions came from bad debt losses on accounts receivable, which had a year-end balance of 211 million yuan [6] Equipment Installation and Market Strategy - The installation pace of flow cytometers and chemiluminescence analyzers in Q1 2025 was significantly faster than the same period last year, with plans to maintain this momentum [7] - The introduction of the small automated chemiluminescence immunoassay analyzer TESMI i50 is expected to enhance market penetration in large hospitals and grassroots healthcare facilities [8] Revenue Structure - The main customer sources remain hospitals, ICL, and health examination centers, with potential growth in grassroots hospitals due to the promotion of TESMI i50 and non-collection projects [9] - Immunoassay reagents continue to be the primary revenue source, with a decline in tumor marker revenue but an expected increase in hormone product revenue; methylation products, particularly lung cancer methylation, showed significant growth compared to the previous year [9]

网址：http://www.cninfo.com.cn 证券代码：300642 证券简称：透景生命 公告编号：2025-029 上海透景生命科技股份有限公司 2025 年第一季度报告披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海透景生命科技股份有限公司（以下简称"公司"）于 2025 年 04 月 25 日召开第四届董事会第十次会议和第四届监事会第七次会议，审议并通过了《关 于公司 2025 年第一季度报告的议案》。为使投资者全面了解公司的经营成果、财 务状况等，公司《2025 年第一季度报告》于 2025 年 04 月 28 日在中国证券监督 管理委员会指定的创业板信息披露网站巨潮资讯网上披露。 敬请广大投资者注意查阅。 特此公告。 上海透景生命科技股份有限公司 董 事 会 2025 年 04 月 28 日 ...